Searched for
U.S. DRUG PRICES
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- School assembly news headlines for June 16: Top national, international, business, sports update and thought of the dayIndia and Slovakia elevate ties to a comprehensive partnership. A rival tutor accuses Khan Sir of murder. Delhi census Phase 1 records over...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Ahead of Market: 10 things that will decide stock market action on MondayMarkets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...
- Dabur India shares in focus after US FDA places drugs from Silvassa plant under import alert. Here’s whyDabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data ...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...
- Trump has a new, surprising take on the higher cost of living: 'I love the inflation'President Trump surprised many by stating he loves inflation. He linked rising prices to the Iran war. Trump also claimed secret military a...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- US stocks: US market rises as tech shares gain, Middle East tensions easeWall Street indexes opened higher on Tuesday, driven by a second consecutive day of gains for chipmakers. Easing Middle East tensions also ...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- US stocks: S&P 500, Nasdaq end up as tech, chipmakers reboundU.S. stocks largely rose Monday, with the Nasdaq and chipmakers leading the gains as investors sought bargains after Friday's selloff. Reli...
- US stocks today: US market gains as semiconductor stocks rebound, Middle East tensions easeMajor Wall Street indexes saw a strong rebound. This recovery was driven by gains in chip stocks. Signs of de-escalation in Middle East ten...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concernsThe oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and or...
- US IPO: Honeywell Quantinuum targets valuation of over $14 billion. Should you buy?Quantinuum's revised IPO terms comes on the heels of the U.S. government unveiling plans last month to take $2 billion in equity stakes acr...
- Honeywell's Quantinuum eyes $14.3 billion valuation in upsized US IPOThe Broomfield, Colorado-based company is now seeking up to $1.46 billion by marketing 26.5 million shares priced between $53 and $55 apiec...
Load More
